Filing Analysis
PMV Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2026. The filing serves as a formal announcement of the earnings press release issued on August 14, 2026.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2026.
- Filing date: August 14, 2026.
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
PMV Pharmaceuticals reported the results of its 2026 Annual Meeting of Stockholders held on June 4, 2026. The stockholders elected two Class III Directors, approved executive compensation on a non-binding advisory basis, and ratified Ernst & Young LLP as the independent auditor for fiscal year 2026.
📋 Key Facts
- Election of David H. Mack, Ph.D. and Laurie Stelzer as Class III Directors to serve until the 2029 annual meeting.
- Executive compensation was approved on a non-binding advisory basis with 15,015,578 votes FOR and 6,468,718 votes AGAINST.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 28,379,108 votes FOR.
PMV Pharmaceuticals, Inc. reported its financial results for the first quarter ended March 31, 2026. The filing serves as a formal disclosure of the company's quarterly performance via an attached press release.
📋 Key Facts
- The report was filed on May 12, 2026, covering the fiscal quarter ended March 31, 2026.
- The disclosure was made under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial results was furnished as Exhibit 99.1.
- The information provided is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
PMV Pharmaceuticals, Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release on March 6, 2026.
📋 Key Facts
- The company reported financial results for the full year ended December 31, 2025.
- The announcement was made on March 6, 2026.
- The financial information was furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- Michael Carulli, CFO, signed the report.
PMV Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the third quarter ended September 30, 2025. The filing serves as a formal notification that a press release containing these results has been issued.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2025.
- Filing date: November 12, 2025.
- The filing includes Exhibit 99.1 (Press Release) containing the financial results.
PMV Pharmaceuticals issued a press release and hosted an investor webinar to present interim clinical data from its PYNNACLE Phase 2 trial for rezatapopt monotherapy. The trial focuses on solid tumors with the TP53 Y220C mutation.
📋 Key Facts
- Announced interim data from the PYNNACLE Phase 2 trial of rezatapopt monotherapy.
- The clinical trial targets multiple solid tumors with a specific TP53 Y220C mutation.
- Hosted an investor webinar on September 10, 2025, to review the clinical data results.
PMV Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2025. The filing serves as a formal notice that a press release containing these results was issued on August 7, 2025.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025.
- Announcement date: August 7, 2025.
- The filing includes a press release as Exhibit 99.1 regarding financial results.
PMV Pharmaceuticals held its 2025 Annual Meeting of Stockholders on June 5, 2025. The meeting resulted in the election of two Class II Directors and the ratification of Ernst & Young LLP as independent auditors, but saw a rejection of executive compensation via a non-binding advisory vote.
🚩 Red Flags
- Shareholder rejection of executive compensation (Say-on-Pay) via a non-binding advisory vote, indicating potential misalignment between management and shareholders regarding pay structures.
📋 Key Facts
- Held virtual Annual Meeting of Stockholders on June 5, 2025.
- Elected Arnold Levine, Ph.D. and Charles M. Baum, M.D., Ph.D. as Class II Directors to serve until the 2028 annual meeting.
- Stockholders voted AGAINST the non-binding advisory proposal regarding executive compensation (11,646,401 FOR vs 20,170,398 AGAINST).
- Ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
- The company will continue non-binding advisory votes on executive compensation until the next scheduled vote in 2028.
PMV Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal mechanism to furnish quarterly earnings information via a press release.
📋 Key Facts
- Report date: May 9, 2025
- Reporting period: First quarter ended March 31, 2024
- The filing includes Exhibit 99.1 containing the full text of the press release regarding financial results.
- Information under Item 2.02 is furnished but not considered 'filed' for purposes of Section 18 liability.
PMV Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of the release of their annual earnings press release.
📋 Key Facts
- Report date: March 3, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The company issued a press release (Exhibit 99.1) containing the financial results.
- The information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
PMV Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the third quarter ended September 30, 2024.
📋 Key Facts
- Report date: November 7, 2024
- Reporting period: Third Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing the financial results.
- The information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
PMV Pharmaceuticals entered into a lease termination agreement for its 50,581 sq. ft. Princeton headquarters, effective September 30, 2024, contingent on the sale of the property. The company is moving to a smaller facility to reduce operating costs.
🚩 Red Flags
- Significant cash outflow ($798k) required within 5 business days of landlord notice.
- Lease termination is explicitly driven by 'continued efforts... to identify cost reduction opportunities,' suggesting liquidity/burn rate management concerns.
📋 Key Facts
- Termination Agreement signed on August 5, 2024, with BMR-One Research Way LLC.
- Lease termination effective September 30, 2024 (subject to property sale contingency).
- Total termination fee of approximately $1.42 million.
- Fee structure: ~$798k cash payment and a ~$622k letter of credit for the security deposit.
- Relocation planned to an alternative property with significantly reduced square footage.
PMV Pharmaceuticals, Inc. held its 2024 Annual Meeting of Stockholders on June 6, 2024. The meeting resulted in the election of two Class I Directors and the ratification of Ernst & Young LLP as the independent auditor.
📋 Key Facts
- Held virtual 2024 Annual Meeting of Stockholders on June 6, 2024.
- Elected Kirsten Flowers and Carol Gallagher, Pharm.D. to Class I Director positions serving until 2027.
- Stockholders approved the non-binding advisory vote regarding executive compensation (Say-on-Pay).
- Ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal year ending December 31, 2024.
PMV Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2024.
- Filing date: May 9, 2024.
- The filing includes a press release (Exhibit 99.1) detailing financial results and operations.
PMV Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: February 29, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Information is furnished under Item 2.02 and not 'filed' for purposes of Section 18 liability.
PMV Pharmaceuticals announced a restructuring plan involving a 30% workforce reduction to streamline operations and preserve capital for the development of its lead candidate, PC14586. The company expects to incur approximately $1.4 million in non-recurring charges, primarily from severance and benefit costs.
🚩 Red Flags
- Significant workforce reduction (30%) often indicates liquidity constraints or a need to extend cash runway.
- The company explicitly states the move is to 'preserve capital', which can be a precursor to more severe financing needs in micro-cap biotech.
📋 Key Facts
- Workforce reduction of approximately 30% of total employees.
- Restructuring expected to be substantially completed by June 30, 2024, and fully completed by end of Q3 2024.
- Estimated aggregate non-recurring charges of approximately $1.4 million.
- Most charges are expected to be cash expenditures recognized in Q1 2024.
- Primary driver for restructuring is capital preservation for late-stage development of PC14586.
PMV Pharmaceuticals announced a significant leadership transition involving the departure of its Chief Operating Officer (COO) and Chief Financial Officer (CFO), Winston Kung, as well as its Chief Medical Officer (CMO), Leila Alland. Michael Carulli has been appointed as the new CFO to succeed Mr. Kung.
🚩 Red Flags
- Simultaneous departure of two key C-suite executives (COO/CFO and CMO) within a single week.
- Significant cash outflows for separation packages and advisory retainers during a period of transition.
📋 Key Facts
- Winston Kung transitioned from COO and CFO effective January 4, 2024; he will serve as an advisor through March 31, 2024 for a $20,000 monthly retainer.
- Michael Carulli appointed as new CFO, principal financial officer, and principal accounting officer effective January 5, 2024.
- Carulli's compensation includes a $370,000 annual base salary and a 40% target cash bonus.
- Leila Alland (CMO) transitioned from her role on January 5, 2024; she will serve as an advisor through March 31, 2024 at a $500 hourly rate.
- The company entered into a separation agreement with Dr. Alland involving a lump sum payment of $76,381.50 and accelerated vesting for 34,800 shares of restricted stock through September 9, 2024.